Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
Mallinckrodt
Colorcon
Dow

Last Updated: September 26, 2022

Details for Patent: 8,573,209


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,573,209 protect, and when does it expire?

Patent 8,573,209 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-four patent family members in thirteen countries.

Summary for Patent: 8,573,209
Title:Gas delivery device and system
Abstract: A gas delivery system including a gas delivery device (100), a control module (200) and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve (107) assembly with a valve and circuit including a memory (134), a processor (122) and a transceiver (120) in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator (400) and a breathing circuit (410). Methods of administering gas are also described.
Inventor(s): Bathe; Duncan P. (Fitchburg, WI), Klaus; John (Cottage Grove, WI), Christensen; David (Cambridge, WI)
Assignee: INO Therapeutics LLC (Hampton, NJ)
Application Number:13/509,873
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,573,209
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 8,573,209

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-002 Dec 23, 1999 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,573,209

PCT Information
PCT FiledJanuary 06, 2011PCT Application Number:PCT/US2011/020319
PCT Publication Date:July 12, 2012PCT Publication Number: WO2012/094008

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
AstraZeneca
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.